KRRO Key Statistics, Chart & Performance
The current stock price of KRRO is 12.3793 USD. In the past month the price increased by 48.43%. In the past year, price decreased by -64.59%.
KRRO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to KRRO. When comparing the yearly performance of all stocks, KRRO is a bad performer in the overall market: 97.12% of all stocks are doing better.
KRRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KRRO. While KRRO has a great health rating, there are worries on its profitability.
KRRO Financial Highlights
Over the last trailing twelve months KRRO reported a non-GAAP Earnings per Share(EPS) of -9.41. The EPS increased by 71.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.73% | ||
| ROE | -89.28% | ||
| Debt/Equity | 0 |
KRRO Forecast & Estimates
16 analysts have analysed KRRO and the average price target is 45.9 USD. This implies a price increase of 270.78% is expected in the next year compared to the current price of 12.3793.
KRRO Ownership
KRRO Latest News, Press Relases and Analysis
KRRO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.81 | 383.716B | ||
| AMGN | AMGEN INC | 16.29 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.74 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.84 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.38 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.06 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.4 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KRRO
Company Profile
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Company Info
KORRO BIO INC
One Kendall Square. Building 600-700, Suite 6-401
Cambridge MASSACHUSETTS US
Employees: 87
Phone: 16174681999
KORRO BIO INC / KRRO FAQ
Can you describe the business of KORRO BIO INC?
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 87 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Can you provide the latest stock price for KORRO BIO INC?
The current stock price of KRRO is 12.3793 USD. The price increased by 0.97% in the last trading session.
What is the dividend status of KORRO BIO INC?
KRRO does not pay a dividend.
What is the ChartMill rating of KORRO BIO INC stock?
KRRO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for KORRO BIO INC?
KORRO BIO INC (KRRO) has a market capitalization of 116.61M USD. This makes KRRO a Micro Cap stock.
Can you provide the upcoming earnings date for KORRO BIO INC?
KORRO BIO INC (KRRO) will report earnings on 2026-03-16, after the market close.
Who owns KORRO BIO INC?
You can find the ownership structure of KORRO BIO INC (KRRO) on the Ownership tab.